Buscar
Mostrando ítems 1-8 de 8
Distribuição dos antígenos de superfície incluídos na vacina meningocócica 4CMenB em amostras brasileiras no período de 2010 a 2015
(Fiocruz/Instituto de Tecnologia em Imunobiológicos, 2018)
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program
(Springer Link, 2014)
Recently approved in Europe and Australia, the
multi-component meningococcal B vaccine, 4CMenB
(Bexsero , Novartis Vaccines and Diagnostics), contains
three surface-exposed recombinant proteins (fHbp, NadA,
and NHBA) ...
From a pathogen’s genome to an effective vaccine: The four-component meningococcal serogroup b vaccine Del genoma de un patógeno a una vacuna efectiva: La vacuna de cuatro componentes frente a los meningococos del serogrupo b
(Sociedad Espanola de Quiminoterapia, 2019)
© 2019, Sociedad Espanola de Quiminoterapia. All rights reserved.Invasive meningococcal disease (IMD), caused by the bacterium Neisseria meningitidis, entails significant mortality and morbidity. Disease incidence is highest ...
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
(Elsevier, 2012-02-18)
Background Effective glycoconjugate vaccines against Neisseria meningitidis serogroups A, C, W-135, and Y have been developed, but serogroup B remains a major cause of severe invasive disease in infants and adolescents ...
Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine
(Taylor & Francis, 2013)
We previously demonstrated the immunogenicity and tolerability of the serogroup B meningococcal vaccine, 4CMenB (Bexsero®), in 11-17 y-olds randomized to receive 1, 2, or 3 doses at 1, 2, or 6 mo intervals. participants ...
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
(Elsevier Ltd, 2019)
Background: Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity ...
Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults
(Elsevier, 2015)
Vaccination programs employing capsular-based meningococcal vaccines have proved successful in a variety of settings globally since first introduced over 40 years ago. Similar successes have been demonstrated using ...